Antithrombotic effects of saratin on human atherosclerotic plaques
Research article published in Thromb Haemost (2004)
Abstract
Platelets play a primary role in thrombus formation after plaque rupture. Platelets recognize the exposed collagen via Von Willebrand factor (VWF) and become activated. Saratin, an inhibitor of the VWF-dependent binding of platelets to collagen, may reduce the thrombotic risk associated to atherosclerosis. Our objective was to evaluate the antithrombotic effects of local treatment with saratin on human atherosclerotic lesions. Thrombus formation was assessed by the deposition of (111)In-platelets on different human atherosclerotic lesions under three local shear conditions (800,1700 and 3400/s) with blood derived from catheterized pigs. Human atherosclerotic lesions were locally treated with saratin (30 microg/ml) at 37 degrees C for 5 min and placed in the chamber. Under stenotic shear conditions of 800/s, saratin significantly (p<0.05) reduced platelet deposition triggered by human denuded vessel wall (44%), fatty streaks (47%), severely damaged vessel (50%) and atherosclerotic plaque (57%). Thrombus characterization by immunohistochemistry showed also a reduction in fibrin deposition in treat-ed vessels. These results suggest that the local site-specific treatment with saratin inhibits atherosclerotic plaque thrombogenicity at haemodynamic conditions typical of moderately stenotic coronary arteries.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Platelets play a primary role in thrombus formation after plaque rupture. Platelets recognize the exposed collagen via Von Willebrand factor (VWF) and become activated.
Por qué esto importa para la hirudoterapia
This ex-vivo study evaluated saratin, described as an inhibitor of von Willebrand factor-dependent platelet binding to collagen, as a local treatment to reduce thrombus formation on human atherosclerotic lesions. Using blood from catheterized pigs perfused over treated plaques, saratin (30 microg/ml) significantly reduced platelet deposition on denuded vessel wall, fatty streaks, severely damaged vessel, and atherosclerotic plaque at 800/s shear, and also reduced fibrin deposition. The abstract does not identify saratin's biological origin and makes no mention of leeches, the leech secretome, or hirudotherapy. There is no defensible connection to ASH's domain based on this abstract. The study used pig blood perfused over human tissue with no clinical data.
Citación
Antithrombotic effects of saratin on human atherosclerotic plaques.
Vilahur G et al. · Thromb Haemost, 2004
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026